Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS

PURPOSE: Since the KRAS mutation is not responsible for all metastatic colorectal cancer (mCRC) patients with resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy, new predictive and prognostic factors are actively being sought. METHODS: We retrospectively ev...

全面介紹

Na minha lista:
書目詳細資料
Main Authors: Kishiki, Tomokazu, Ohnishi, Hiroaki, Masaki, Tadahiko, Ohtsuka, Kouki, Ohkura, Yasuo, Furuse, Jyunji, Watanabe, Takashi, Sugiyama, Masanori
格式: Artigo
語言:Inglês
出版: Springer Berlin Heidelberg 2014
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC3965831/
https://ncbi.nlm.nih.gov/pubmed/24500024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-014-2401-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍